KRAIG BIOCRAFT LABORATORIES, INC. (OTCMKTS:KBLB) Files An 8-K Regulation FD Disclosure
Item 7.01: Regulation FD Disclosure
On or about July 13, 2019, Kraig Biocraft Laboratories, Inc. (the “Company”) will complete the mailings of notice to its shareholders regarding the Company’s upcoming annual shareholder meeting. The shareholder meeting will be held at 10:00 a.m., eastern standard time, at East Lansing Marriott at University Place, 300 M. A. C. Ave, East Lansing, MI 48823, on July 24,2019, for the purpose of considering and voting upon several proposals, as set forth in the notice, which is attached hereto as Exhibit 99.1
The notice and related proxy card will be mailed to each shareholder entitled to vote at the annual meeting. Shareholders are urged to read the entire notice as it contains important information about the proposed corporate actions.
After the annual meeting, we will file an amendment to this Report to disclose the voting results.
The information included in Item 7.01 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under theSecurities Act of 1933, as amended (the “Securities Act”), or theExchange Act, except as expressly set forth by specific reference in such filing.
On July 8, 2019, the Company issued a press release announcing the annual shareholder meeting and related information. A copy of the press release is filed as Exhibit99.2 to this Current Report on Form8-K and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
Kraig Biocraft Laboratories, Inc Exhibit
EX-99.1 2 ex991.htm ADDITIONAL EXHIBITS Blueprint KRAIG BIOCRAFT LABORATORIES,…
To view the full exhibit click
About KRAIG BIOCRAFT LABORATORIES, INC. (OTCMKTS:KBLB)
Kraig Biocraft Laboratories, Inc. is a biotechnology company focused on the development and commercialization of spider silks. The Company’s lead product is a genetically engineered spider silk known as Monster Silk. Monster Silk is a composite fiber, which is spun by its line of transgenic silkworms. Monster Silk is composed of a combination of both spider silk proteins and silk from a silkworm. The Company uses genetic engineering technologies to develop fibers for use in target markets, including the textile, specialty fiber and technical textile industries. Specialty fibers are engineered for specific uses that require strength, flexibility, heat resistance and/or chemical resistance. The technical textile industry involves products for both industrial and consumer products, such as filtration fabrics, medical textiles (such as sutures and artificial ligaments), safety and protective clothing, and fabrics used in military and aerospace applications.
An ad to help with our costs